RBC Capital raised the firm’s price target on Ligand (LGND) to $234 from $185 and keeps an Outperform rating on the shares after “another solid quarter” and 2025 guidance raise.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $220 from $195 at Stifel
- Ligand price target raised to $220 from $175 at Benchmark
- Ligand price target raised to $275 from $250 at Oppenheimer
- Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer
- Ligand Pharmaceuticals Reports Strong Q3 Results and Raises Guidance